GlassScriptPhysician profile
Shabana Karim
NPI 1992903355
$12,215.37
in general payments reported to CMS, 2019-2025
29 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $1,557 · 2021: $2,095 · 2022: $1,930 · 2023: $1,782 · 2024: $1,587 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,922 · Education: $65.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,921.61 |
| Education | $65.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,056.29 | 2019-2025 | Enbrel, Evenity, Tavneos |
| Abbvie INC. | $1,858.42 | 2019-2025 | |
| Ucb, INC. | $1,119.23 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $816.44 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $798.60 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $647.84 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $536.07 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $498.11 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $493.12 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $376.15 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.79 | 2020-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $278.36 | 2020-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $265.83 | 2019-2025 | Sotyktu |
| Ani Pharmaceuticals, INC. | $221.81 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $176.38 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $140.70 | 2019-2020 | |
| Sobi, INC | $139.26 | 2022-2025 | |
| Genzyme Corporation | $127.97 | 2020-2021 | |
| Penumbra, INC. | $118.28 | 2025 | Indigo System |
| Organon LLC | $45.83 | 2024-2025 | Hadlima, Renflexis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.08 | 2020 | |
| Bioventus LLC | $32.20 | 2019 | |
| Fresenius Kabi USA, LLC | $19.76 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $18.36 | 2022 | |
| Genentech USA, INC. | $18.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.13 | 2022 | |
| Hikma Pharmaceuticals USA | $12.96 | 2021 | |
| Sanofi Pasteur INC. | $12.12 | 2019 | |
| Depuy Synthes Sales INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shabana Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.